

Success! In Clinical Laboratory Science - Hemostasis Practice Test (Sample)

Study Guide



Everything you need from our exam experts!

Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright	1
Table of Contents	2
Introduction	3
How to Use This Guide	4
Questions	5
Answers	9
Explanations	11
Next Steps	17

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 - 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

SAMPLE

- 1. Which laboratory test is decreased during a DIC event?**
 - A. Fibrinogen**
 - B. PT**
 - C. aPTT**
 - D. Antithrombin**

- 2. The hemorrhagic problems associated with scurvy are due to a deficiency of what cofactor required for collagen synthesis?**
 - A. Vitamin C**
 - B. Prothrombin**
 - C. Vitamin K**
 - D. Protein C**

- 3. A 35-year-old male presents with sudden severe hemorrhagic problems. Platelet count is normal, PFA-100 is normal, PT is normal, aPTT is markedly prolonged and does not correct after a 1:1 mixing study. These findings are most consistent with which diagnosis?**
 - A. Lupus anticoagulant**
 - B. von Willebrand disease**
 - C. Hemophilia A**
 - D. Factor VIII inhibitor**

- 4. A 65-year-old patient with elevated PT/INR and suspected intracranial bleed; on oral blood thinners but the medications are not with her and she cannot communicate. Which medication would be suspected?**
 - A. Plavix**
 - B. Aspirin**
 - C. Coumadin**
 - D. Enoxaparin**

- 5. Which pair of drugs is listed as antiplatelet medications in the source material?**
- A. Aspirin and Plavix**
 - B. Coumadin and Heparin**
 - C. Heparin and Protamine**
 - D. Tissue plasminogen activator and Streptokinase**
- 6. What is the most likely factor deficiency based on the following data? PT Normal, aPTT Prolonged, TT Normal**
- A. FVII**
 - B. FII**
 - C. FIX**
 - D. FXIII**
- 7. Which thrombolytic agent is used for acute ischemic stroke?**
- A. Aspirin**
 - B. Heparin**
 - C. Tissue plasminogen activator**
 - D. Warfarin**
- 8. Which group of coagulation factors are vitamin K-dependent?**
- A. II, VII, IX, X**
 - B. I, II, V, VIII**
 - C. XI, XII, Fletcher, Fitzgerald**
 - D. III, IV, V, VI**
- 9. Which of the following is the final normal maturation stage for platelets?**
- A. Megakaryoblast**
 - B. Promegakaryocyte**
 - C. Thrombocyte**
 - D. Megakaryocyte**

10. In this patient, which anticoagulant was used to obtain PT and aPTT results from the blood sample?

- A. EDTA**
- B. Sodium citrate**
- C. Heparin**
- D. Fluoride**

SAMPLE

Answers

SAMPLE

1. A
2. A
3. D
4. C
5. A
6. C
7. C
8. A
9. C
10. B

SAMPLE

Explanations

SAMPLE

1. Which laboratory test is decreased during a DIC event?

- A. Fibrinogen**
- B. PT**
- C. aPTT**
- D. Antithrombin**

In DIC, clotting factors and platelets are consumed as microthrombi form throughout the circulation, creating a consumption coagulopathy. Fibrinogen is one of the factors used up to make fibrin, so its level drops during an active DIC event. That's why fibrinogen is decreased. In contrast, the time-based clotting tests (prothrombin time and aPTT) are typically prolonged because the clotting factors are depleted, not reduced in activity to a lower level. Antithrombin can also be reduced due to consumption, but the hallmark decrease you'd expect to see in this scenario is fibrinogen.

2. The hemorrhagic problems associated with scurvy are due to a deficiency of what cofactor required for collagen synthesis?

- A. Vitamin C**
- B. Prothrombin**
- C. Vitamin K**
- D. Protein C**

The issue in scurvy hemorrhages is impaired collagen maturation caused by lack of vitamin C. Ascorbic acid acts as a reducing cofactor for the enzymes that hydroxylate specific amino acids—proline and lysine—in procollagen. This hydroxylation is necessary for the collagen triple helix to form correctly and for collagen to be stable and secreted into the extracellular matrix. When this step is defective, collagen fibers are weak, making blood vessel walls fragile and prone to hemorrhage, which explains the easy bruising, gum bleeding, and poor wound healing seen in scurvy. The other options involve components of the coagulation system; deficiencies here cause bleeding from insufficient clot formation rather than the collagen synthesis defect characteristic of scurvy. Therefore, vitamin C is the essential cofactor missing.

3. A 35-year-old male presents with sudden severe hemorrhagic problems. Platelet count is normal, PFA-100 is normal, PT is normal, aPTT is markedly prolonged and does not correct after a 1:1 mixing study. These findings are most consistent with which diagnosis?

- A. Lupus anticoagulant**
- B. von Willebrand disease**
- C. Hemophilia A**
- D. Factor VIII inhibitor**

When the aPTT is markedly prolonged and does not correct after a 1:1 mixing study with normal plasma, the pattern points to an inhibitor against a clotting factor rather than a simple deficiency. Here, the findings fit an acquired antibody against factor VIII. That autoantibody neutralizes factor VIII in both the patient's plasma and the added normal plasma, so the intrinsic pathway remains impaired and the aPTT stays prolonged. The normal platelet count and a normal PFA-100 indicate platelet function is intact, and the normal PT shows the extrinsic pathway is unaffected, focusing the problem on the intrinsic pathway where factor VIII operates. Among possibilities, a lupus anticoagulant can also prolong the aPTT and resist mixing, but it typically associates with thrombosis rather than severe bleeding, making an anti-factor VIII inhibitor a more consistent explanation for this bleeding presentation. Von Willebrand disease would usually affect platelet adhesion and often alter PFA-100 results, and a congenital factor VIII deficiency would typically correct with mixing, not persist as prolonged. So, the most consistent diagnosis is an acquired factor VIII inhibitor (acquired hemophilia A).

4. A 65-year-old patient with elevated PT/INR and suspected intracranial bleed; on oral blood thinners but the medications are not with her and she cannot communicate. Which medication would be suspected?

- A. Plavix**
- B. Aspirin**
- C. Coumadin**
- D. Enoxaparin**

The main idea is that PT/INR specifically reflects the extrinsic pathway of coagulation and is most affected by an oral vitamin K antagonist. Coumadin (warfarin) inhibits vitamin K-dependent clotting factors II, VII, IX, and X, which prolongs the prothrombin time and raises the INR. In a patient with suspected intracranial bleeding who is on an oral anticoagulant, a high INR points to warfarin as the likely medication in use. Aspirin and Plavix are antiplatelet drugs; they impair platelet function and increase bleeding risk but do not shorten or lengthen the PT/INR. Enoxaparin is a low-molecular-weight heparin given by injection and more commonly affects the aPTT/anti-Xa tests rather than the PT/INR. Therefore, the pattern described fits warfarin, the oral anticoagulant.

5. Which pair of drugs is listed as antiplatelet medications in the source material?

- A. Aspirin and Plavix**
- B. Coumadin and Heparin**
- C. Heparin and Protamine**
- D. Tissue plasminogen activator and Streptokinase**

Antiplatelet drugs work by preventing platelets from clumping together, reducing arterial thrombosis risk. Aspirin blocks COX-1 in platelets, so less thromboxane A2 is made and platelet aggregation decreases. Plavix (clopidogrel) blocks the platelet ADP receptor P2Y12, stopping ADP-mediated activation and aggregation. Together, they are classic antiplatelet agents. The other pairs don't fit that category: Coumadin (warfarin) is an anticoagulant that inhibits vitamin K-dependent clotting factors; heparin is another anticoagulant that enhances antithrombin III. Protamine is a reversal agent for heparin. Tissue plasminogen activator and streptokinase are thrombolytics that dissolve existing clots by activating plasmin, not by preventing platelet aggregation. So the pair listed as antiplatelet medications is aspirin and Plavix.

6. What is the most likely factor deficiency based on the following data? PT Normal, aPTT Prolonged, TT Normal

- A. FVII**
- B. FII**
- C. FIX**
- D. FXIII**

The pattern tests the different coagulation pathways. A normal PT indicates the extrinsic pathway is functioning, while a prolonged aPTT points to a problem in the intrinsic pathway or the common pathway. A normal thrombin time means the final step of converting fibrinogen to fibrin by thrombin is intact, so the issue is before thrombin acts, not with the conversion of fibrinogen or with crosslinking. Among the intrinsic pathway factors listed, a deficiency in Factor IX specifically impairs the intrinsic pathway enough to prolong the aPTT, but it does not affect the extrinsic pathway (normal PT) or the final thrombin-mediated conversion of fibrinogen to fibrin (normal TT). This pattern fits Factor IX deficiency (hemophilia B) best. Deficiencies in FII would typically prolong thrombin time because thrombin generation is impaired, and FXIII deficiency would not prolong the aPTT at all. FVII deficiency would prolong PT, not aPTT.

7. Which thrombolytic agent is used for acute ischemic stroke?

- A. Aspirin**
- B. Heparin**
- C. Tissue plasminogen activator**
- D. Warfarin**

The key idea is dissolving the clot that blocks blood flow in the brain. A thrombolytic that does this activates plasminogen to plasmin, which breaks down fibrin in the clot. Tissue plasminogen activator does exactly this and is given intravenously to restore blood flow in acute ischemic stroke, ideally within a limited time window after onset and in patients who meet safety criteria. This direct clot-dissolving action is what makes it the best choice for acute treatment. Aspirin, by contrast, helps prevent further platelet clumping but does not rapidly dissolve an existing clot. Heparin and warfarin are anticoagulants that affect the coagulation cascade to prevent new clots or the growth of existing ones over time, not to lyse the current clot quickly, and they carry bleeding risks if used in the acute stroke setting.

8. Which group of coagulation factors are vitamin K-dependent?

- A. II, VII, IX, X**
- B. I, II, V, VIII**
- C. XI, XII, Fletcher, Fitzgerald**
- D. III, IV, V, VI**

Vitamin K is required to activate certain coagulation factors by enabling gamma-carboxylation, which lets them bind calcium and attach to phospholipid surfaces during clot formation. The factors that undergo this modification are II (prothrombin), VII, IX, and X. Therefore, this group is vitamin K-dependent. Without this carboxylation, these factors are produced but inactive, leading to impaired clotting; drugs like warfarin inhibit the recycling of vitamin K, reducing activity of these factors. Other listed factors, such as fibrinogen (I) and cofactors V and VIII, do not require vitamin K for their activation, so they're not vitamin K-dependent groups. Some items mentioned (like tissue factor, calcium as a separate factor, or non-existent factors) aren't classic coagulation factors, so they don't fit the vitamin K-dependence pattern.

9. Which of the following is the final normal maturation stage for platelets?

- A. Megakaryoblast**
- B. Promegakaryocyte**
- C. Thrombocyte**
- D. Megakaryocyte**

Understanding how platelets mature helps you see why the final stage is thrombocyte. Platelets come from megakaryocytes in the bone marrow. The development sequence starts with a megakaryoblast, then progresses to a promegakaryocyte, and finally to a megakaryocyte. The megakaryocyte grows large and extends cytoplasmic processes; these processes fragment to release small, anucleate platelet pieces into the bloodstream. Those circulating platelets are called thrombocytes. So the last normal maturation stage for platelets is thrombocyte, because it represents the fully formed, functional platelet fragment ready to participate in hemostasis. The earlier terms—megakaryoblast, promegakaryocyte, and megakaryocyte—are precursor stages preceding platelet formation.

10. In this patient, which anticoagulant was used to obtain PT and aPTT results from the blood sample?

- A. EDTA**
- B. Sodium citrate**
- C. Heparin**
- D. Fluoride**

Coagulation tests such as PT and aPTT are performed on citrated plasma because citrate binds calcium to prevent clotting in the collection tube, while still allowing the test to proceed once calcium is reintroduced during the assay. The calcium reversal is what lets the clotting cascade run in a controlled, measured way, giving accurate times. Sodium citrate is the anticoagulant of choice here because it preserves the coagulation factors in plasma without permanently disabling them. It's a reversible chelator, so when the lab adds calcium during the test, clotting can occur normally and the results reflect the factors' true activity. Other options don't fit. EDTA also chelates calcium, but it's used mainly for preserving blood cells in CBCs and would distort coagulation times. Fluoride is used with oxalate to preserve glucose and is not appropriate for coagulation testing. Heparin prevents clotting by enhancing antithrombin and would alter the coagulation cascade in a way that makes PT/aPTT results unreliable for assessing the intrinsic and extrinsic pathways.

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

<https://sucessinclinicalabhemostasis.examzify.com>

We wish you the very best on your exam journey. You've got this!

SAMPLE